CaseTrail

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/s

566 U.S. 399 · Decided April 17, 2012 · Supreme Court of the United States

Record summary. This page is generated from the Supreme Court Database’s coded data about the case. It describes who decided what, not the Court’s reasoning. Read the opinion itself before relying on it. Not legal advice.

At a glance

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/s was decided on April 17, 2012 unanimously (9–0). The Court reversed the lower court's decision and remanded the case. Justice Elena Kagan wrote the opinion of the Court. SCDB classifies its main issue as “Consumer protection” in the Economic Activity area.

Read the opinion

Case details

Citations
566 U.S. 399 · 132 S. Ct. 1670 · 182 L. Ed. 2d 678 · 2012 U.S. LEXIS 3106
Docket number
10-844
Decided
April 17, 2012
Argued
December 5, 2011
Court era
Roberts Court
Decision type
Opinion of the Court (orally argued)
Disposition
Reversed and remanded
Outcome for petitioner
The petitioning party received a favorable disposition
Vote
9–0 (unanimous)
Majority opinion
Elena Kagan
Opinion assigned by
John G. Roberts Jr.
How the case arrived
Certiorari
Legal provision
21-355
Type of law
Infrequently litigated statute
Decision direction (SCDB)
Liberal what this means

How the Justices voted

Full case caption

Caraco Pharmaceutical Laboratories, Ltd., et Al., Petitioners v. Novo Nordisk A/s et al.

SCDB identifiers: case 2011-047, docket 2011-047-01.

Other cases on “Consumer protection”

See all

Same Term, same area (Economic Activity)

See all

Source: Supreme Court Database, 2026 Release 01 (data file dated September 8, 2026). Imported into CaseTrail November 5, 2026. Coverage: decisions from the 1946 through 2025 Terms. Methodology · Report an error